Bethanechol Chloride (25mg) & BETHNEVOID 25 Tablet - Steris Healthcare PVT LTD………

BETHNEVOID 25 

Bethanechol Chloride (25mg)

Bethnevoid 25 emerges as a vital medication in the treatment of urinary retention, offering individuals relief from the discomfort and complications associated with this condition. In this comprehensive guide, we delve into the intricate details of Bethanechol Chloride (25mg) including its mechanism of action, clinical indications, dosage guidelines, potential side effects, and essential precautions.

Mechanism of Action:
Bethnevoid 25 contains bethanechol chloride as its active ingredient, which acts as a cholinergic agonist. By stimulating muscarinic receptors in the bladder smooth muscle, Bethnevoid 25 enhances detrusor muscle contraction and promotes bladder emptying. This mechanism helps alleviate urinary retention by facilitating the expulsion of urine from the bladder.

Clinical Indications:
Bethnevoid 25 is indicated for the treatment of urinary retention, a condition characterized by the inability to empty the bladder. It may be prescribed in various clinical scenarios, including postoperative urinary retention, neurogenic bladder dysfunction, and non-obstructive urinary retention. Additionally, Bethnevoid 25 may be used to improve bladder emptying in individuals with urinary retention due to impaired bladder contractility.

Dosage Guidelines:
The dosage of Bethnevoid 25 should be individualized based on factors such as the underlying cause of urinary retention, the patient's age, and renal function. Typically, the recommended starting dose is 10 to 50 mg orally three to four times daily, with gradual dose titration based on the patient's response. Bethnevoid 25 is usually taken on an empty stomach to enhance absorption and minimize gastrointestinal side effects.

Potential Side Effects:
While Bethnevoid 25 is generally well-tolerated, it may be associated with certain adverse effects. Common side effects include abdominal cramps, nausea, vomiting, diarrhea, and increased salivation. Additionally, Bethnevoid 25 may cause cholinergic effects such as bradycardia, bronchoconstriction, and lacrimation. Patients should be educated about these potential side effects and instructed to report any concerning symptoms to their healthcare provider.

Essential Precautions:
Several precautions should be observed while using Bethnevoid 25. Patients with a history of asthma, peptic ulcer disease, urinary tract obstruction, or cardiovascular disease should use Bethnevoid 25 with caution, as it may exacerbate these conditions. Moreover, Bethnevoid 25 should be used cautiously in elderly patients, as they may be more susceptible to adverse effects. Regular monitoring of bladder function and vital signs is recommended during treatment.

In conclusion, Bethnevoid 25 emerges as a valuable pharmacological tool in the management of urinary retention, offering individuals relief from the distressing symptoms and complications associated with this condition. However, its use requires careful consideration of dosage, monitoring for potential side effects, and adherence to essential precautions. By harnessing the therapeutic potential of Bethnevoid 25 judiciously, healthcare providers can optimize treatment outcomes and improve the quality of life for individuals affected by urinary retention. Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands: gynecology, Pediatrics, Dental care, and Dermatology. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

 For further information: 

  EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

 BUY NOW